CHMP recommends Evarrest Sealant Matrix (Omrix Biopharm) for improvement of Haemostasis
On 27 June 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Evarrest Sealant Matrix to Omrix Biopharmaceuticals NV/Ehticom Biosurgery. This recommendation will now be forwarded to the European Commission, which will issue a legally binding decision. The indication recommended by the CHMP is as follows: �EVARREST is indicated in adults for supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis�. EVARREST should only be prescribed by experienced surgeons.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins